Tesamorelin Half-Life Calculator
Tesamorelin is a GHRH analogue and — unusually among the growth hormone secretagogues and releasing factors — an FDA-approved medicine with a specific indication. Its half-life is very short, measured in minutes.
Half-life 8 min · peaks at 9 min
Every 24 hours.
Half-life
Left at next dose
Tesamorelin · once daily · levels plateau after ~40 min
Steady-state peak
0.63 mg
Steady-state trough
0 mg
Accumulation
None
At once daily, each dose has essentially cleared before the next one — levels don't accumulate, they repeat the same rise and fall. Clearance after a dose takes about 40 min.
This is a modelled estimate of relative levels from published half-life and time-to-peak figures — not a measured blood concentration. Individual pharmacokinetics vary.
Based on a published Tesamorelin half-life of about 8 min. The chart models RELATIVE levels from a unit dose — enter your own figures to see the shape. It is not a dose recommendation.
Never do this math twice.
The Pep AI app remembers your vials and doses, shows an interactive syringe you draw to, counts down the doses left in each vial, and reminds you when it's time. Free on iOS and Android.
What a 8 min half-life means in practice
A half-life of 8 min against once daily dosing means each dose has essentially cleared before the next arrives. That shapes the curve in three ways:
1. One half-life
Half the dose is gone after 8 min. After two half-lives 25% remains, after three 12.5%.
2. What's left at the next dose
Dosing once daily means the next dose lands 24 hours later, with about 0% of the previous one still present.
3. Accumulation and plateau
Almost nothing carries over, so levels don't accumulate — each dose repeats the same rise and fall, clearing in about 40 min.
Worked example
Tesamorelin has a half-life of 8 min. Dosing once daily, the next dose arrives 24 hours later with about 0% of the previous one still on board. That's little enough that levels don't build up: each dose rises and falls on its own, clearing in about 40 min.
Approved, for a specific indication
Tesamorelin holds FDA approval for reducing excess visceral abdominal fat in HIV-associated lipodystrophy. That is a narrow, specific indication with clinical trial data behind it, and it makes tesamorelin genuinely different in kind from the unapproved compounds it sits alongside in catalogues.
Approval for one indication is not approval in general. The trial evidence supports the approved use in the approved population; it does not establish anything about use for other purposes or in other groups, and the prescribing information is written for the indication it was granted. Its half-life is a matter of minutes, so administrations do not accumulate.
Frequently asked questions
This calculator is provided for informational and educational purposes only and is not medical advice. Always confirm dosing with a qualified healthcare professional and double-check your own measurements before administering anything.
Built by the Pep AI team.